Drug
Nnc6019 0001
Nnc6019 0001: highest development phase Phase 3, developed by Novo Nordisk. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Novo Nordisk
Trials
| Drug | Phase | Indication |
|---|---|---|
| NNC6019-0001 NCT07207811 | Phase 3 | Transthyretin Amyloid Cardiomyopathy (ATTR CM) |
Latest
No recent events.
Follow Nnc6019 0001 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.